Luminate Medical

Discover how Luminate Medical is revolutionising cancer treatment by reducing chemotherapy side effects and enabling at-home care. Read more about their latest innovations

ARTIS Ventures recently led a $15M Series A into Luminate Medical, led by Aaron Hannon. We're excited at their potential to transform the chemotherapy treatment process by reducing side effects for patients, lowering costs for payers, and unlocking value for private practice oncologists across the United States. Welcome to the Artis portfolio family!

Luminate Medical (YC S21) has raised $15 million in Series A funding to make medical devices that stop the side effects of cancer treatment. Their first product, Lily, is a wearable cap that enables chemotherapy patients to prevent hair loss in a comfortable, portable way. The helmet applies even pressure on the scalp to block capillaries, stopping the harmful chemotherapy from reaching hair follicles. In initial tests, this method helped 75% of users keep their hair. "We’ve had patients finish four to 12 chemo treatments and keep a full head of hair. There’s been incredible feedback about how it’s changed their experience of going through treatment," said co-founder and CEO Aaron Hannon. The tests also showed that there were few, if any, safety, comfort, or device issues, and that wearing the helmet for longer actually improved outcomes. The next step is a multi-center study in the U.S. for FDA clearance. The team also found that pressure technology could help reduce chemo-induced neuropathy, which is nerve damage in the extremities. Their next medical device, Lilac, works like a precision compression sock or glove to provide more accurate and consistent pressure. It's the world's first device to prevent peripheral nerve damage caused by cancer treatment. Congrats Aaron, Barbara Oliveira, and the entire team at Luminate on the Series A! https://lnkd.in/gK8eJaJ4

If there is one thing you can say for Aaron Hannon, the chief executive of Luminate Medical, it is that he doesn’t lack ambition. “Our long term vision is that we want to deliver every cancer treatment at home, rather than in clinical settings as is typically the case now,” he says.

Luminate Medical is excited to announce our $15m Series A led by ARTIS Ventures, with participation from Metaplanet, Lachy Groom and 8VC. This funding will enable the company to move its Lily and Lilac devices, designed to prevent hair loss and peripheral neuropathy during chemo, towards FDA clearance, and add 30 new roles at our Galway HQ. https://lnkd.in/eGc4-Mze

The Luminate team has arrived at #ESMO24 - excited to be here and connect with oncologists, nurses, patient advocates to change the face of cancer care! Barbara Oliveira Cathy O'Boyle Gavin Reynolds

Congratulations to our very own Olivia Humphreys on her incredible achievement this week 👏

We're hiring for a Senior R&D Engineer to work on our Lilac project! Funded by a €4.4M grant from Enterprise Ireland's DTIF program, Lilac aims to become the first FDA-approved technology to prevent the onset of peripheral nerve damage in chemotherapy patients.

Luminate Medical’s clinical team has been busy! Join Barbara Oliveira and Kimberly Wilkinson as they head to #ASCO24 in Chicago to keep exploring how to drive better #patientoutcomes and #qualityoflife for #cancer patients!

Join Luminate Medical's Co-Founder and Chief Clinical Officer Barbara Oliveira as she takes the stage tomorrow at the Dublin Tech Summit to discuss innovation for better patient outcomes, a core value behind Luminate's mission to help patients live better lives through cancer treatment!